JP Morgan Chase’s Ligand Pharmaceuticals LGND Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q2
Sell
-57,868
Closed -$2.63M 5551
2020
Q1
$2.63M Sell
57,868
-496,129
-90% -$28.1M ﹤0.01% 2763
2019
Q4
$36M Hold
553,997
0.01% 1157
2019
Q3
$34.4M Buy
+553,997
New +$34.8M 0.01% 1177
2019
Q2
Sell
-103,714
Closed -$8.13M 5892
2019
Q1
$8.13M Sell
103,714
-306,013
-75% -$23.2M ﹤0.01% 2228
2018
Q4
$34.7M Buy
+409,727
New +$43.7M 0.01% 1095
2017
Q1
Sell
-24,045
Closed -$1.52M 5152
2016
Q4
$1.52M Buy
+24,045
New +$1.52M ﹤0.01% 3237

Other funds holding LGND

JP Morgan Chase's LGND Position: Q1 2026 in Review

JP Morgan Chase increased its Ligand Pharmaceuticals (LGND) stake by 52% in Q1 2026, buying an estimated $5.87M and bringing the position to 86,274 shares worth $16.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2235.

JP Morgan Chase first reported a position in LGND in Q2 2013 and has held it in 45 quarters since. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • JP Morgan Chase held 86,274 shares of Ligand Pharmaceuticals worth $16.6M as of Q1 2026.
  • JP Morgan Chase bought 29,684 Ligand Pharmaceuticals shares in Q1 2026, an estimated $5.87M.
  • Ligand Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #2235 holding.
  • JP Morgan Chase first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 45 quarters since.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.